American pharmaceutical company Pfizer and German biotechnology company BioNTech have taken their clinical trial for a COVID-19 vaccine to the next step. They jointly announced this Tuesday that they have started human trials in the United States.
Called BNT162, their vaccine program began human trials in Germany during the last week of April. Part of the program’s Phase 1/2 study is a simultaneous trial happening in the US, specifically at the NYU Grossman School of Medicine in New York and the University of Maryland School of Medicine.
The study is designed to test the safety, effectiveness, and best dose level of four mRNA vaccine candidates. All of these will be evaluated in a single, continuous study.
The trial includes volunteers between the ages of 18 and 55 who will be given doses ranging from 1µg (microgram) to 100µg “to find the optimal dose for further studies.”
Should the results of the trials come out favorably, the 2 companies are prepared to produce millions of doses in a matter of months.
What do you think about this?
Do you have a story for the WhenInManila.com Team? Email us at firstname.lastname@example.org or send us a direct message at WhenInManila.com Facebook Page. Interact with the team and join the WhenInManila.com Community at WIM Squad! Join our WhenInManila.com community on Viber, as well!